Search

UCB SA

Suletud

SektorTervishoid

227.5 -1.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

224.1

Max

231.8

Põhinäitajad

By Trading Economics

Sissetulek

28M

1.1B

Müük

16M

4.3B

P/E

Sektori keskmine

19.558

68.51

Aktsiakasum

5.7

Dividenditootlus

0.65

Kasumimarginaal

26.019

Töötajad

9,000

EBITDA

587M

1.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.65%

2.29%

Turustatistika

By TradingEconomics

Turukapital

-5.5B

41B

Eelmine avamishind

228.67

Eelmine sulgemishind

227.5

Uudiste sentiment

By Acuity

100%

0%

323 / 340 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4. aug 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4. aug 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4. aug 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4. aug 2026, 23:51 UTC

News

Cooper-Standard Holdings will present at the J.P. Morgan 2026 Auto Conference on August 12, with a focus on business strategies. Shares traded little changed after hours.

4. aug 2026, 23:51 UTC

News

Teradata Corp shares fell in after-market hours following mixed Q2 results and disappointing Q3 guidance, projecting adjusted EPS of $0.55 to $0.59.

4. aug 2026, 23:51 UTC

News

8x8 Inc. shares are lower in after-market hours following mixed first-quarter results, with revenue exceeding expectations but second-quarter EPS guidance falling short.

4. aug 2026, 23:51 UTC

News

Hyster-Yale Materials Handling shares fell in after-market trading following a second-quarter revenue of $812.9 million and a net loss of $31.6 million.

4. aug 2026, 23:51 UTC

Social Media
News

Arista Networks shares higher in after-market hours following strong second-quarter results, with adjusted EPS of $1.02 and optimistic third-quarter guidance.

4. aug 2026, 23:51 UTC

News
Social Media

Hecla Mining Co reported second-quarter EPS of $0.17 and revenue of $333.85 million, exceeding expectations. Shares are higher in after-market trading.

4. aug 2026, 23:51 UTC

Correlated Moves
ETF Constituents
News
Macro News

Vanguard Information Technology ETF is trading higher in after-market hours, supported by strong earnings from tech stocks and positive sentiment from UBS's coupon payments.

4. aug 2026, 23:46 UTC

News

Teladoc Health faces scrutiny amid revenue miss and lowered outlook. Shares traded roughly flat in after-market hours following the developments.

4. aug 2026, 23:42 UTC

News

Apple Inc. seeks a preliminary injunction against OpenAI amid a legal battle, as shares trade higher in after-market hours.

4. aug 2026, 23:41 UTC

News

Shutterstock shares are higher in after-market hours despite a $155.9 million net loss and a $173.7 million goodwill impairment charge reported for Q2.

4. aug 2026, 23:41 UTC

News

Compass Inc. shares rise in after-market hours following strong Q2 revenue of $4.306 billion and optimistic Q3 guidance of $3.85 billion to $4.05 billion.

4. aug 2026, 23:41 UTC

News
Social Media

Lumen Technologies reported second-quarter revenue of $2.805 billion, exceeding estimates. Shares rose after hours as the company reaffirmed its full-year guidance.

4. aug 2026, 23:41 UTC

News

Flywire Corp reported strong Q2 results, with revenue surpassing estimates. Shares are higher in after-market trading following the raised full-year guidance.

4. aug 2026, 23:41 UTC

News

Community Healthcare Trust shares declined in after-market hours following second-quarter results that missed earnings and revenue expectations. EPS was $0.06 versus an estimated $0.12.

4. aug 2026, 23:41 UTC

News

Bruker shares higher in after-market hours following Jefferies' price target increase to $62.00, maintaining a Buy rating amid broader performance challenges.

4. aug 2026, 23:41 UTC

Social Media
News

Alphabet Inc shares are higher in after-market trading following the expansion of its Gemini feature in Google Classroom for K-12 users.

4. aug 2026, 23:41 UTC

News
Social Media

Zeta Global Holdings reported Q2 revenue of $443 million but shares fell in after-market trading amid mixed reactions and concerns over growth guidance.

4. aug 2026, 23:41 UTC

Social Media
News

Palantir Technologies reported strong second-quarter results but shares fell during after-market hours, overshadowed by broader market gains and mixed sentiment.

4. aug 2026, 23:41 UTC

Social Media
News

Rocket Lab USA Inc secures a $397 million contract from the U.S. Space Force, driving shares higher in after-market trading.

4. aug 2026, 23:41 UTC

News

IDEXX Laboratories reported second-quarter revenue of $1.22 billion, a 9.7% increase year-over-year. Shares are trading higher in after-market hours following the results.

4. aug 2026, 23:41 UTC

Social Media
News

Kratos Defense and Security Solutions reported Q2 revenues of $458.8 million, exceeding estimates. Shares are advancing in after-market trading amid raised sales guidance.

4. aug 2026, 23:36 UTC

News

EOG Resources reported strong Q2 earnings of $5.15 per share and revenues of $8.62 billion, contributing to shares trading higher in after-market hours.

4. aug 2026, 23:36 UTC

News

Alphatec Holdings shares fell in after-market trading following a net loss of $26 million, despite meeting adjusted EPS expectations and exceeding revenue forecasts.

4. aug 2026, 23:36 UTC

News

Dell Technologies reported nearly 40% of revenue now from AI initiatives. Shares are lower in after-market trading following the announcement.

4. aug 2026, 23:36 UTC

News

Marathon Petroleum shares higher in after-market trading, reflecting stable performance and a market capitalization of approximately $91.74 billion.

4. aug 2026, 23:36 UTC

News

Western Union has launched the Stablecard for international transfers, but shares are trading lower in after-market hours following routine trading activity.

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

323 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
help-icon Live chat